Mortality, Causes of Death and Associated Factors Relate to a Large HIV Population-Based Cohort

Introduction Antiretroviral therapy has led to a decrease in HIV-related mortality and to the emergence of non-AIDS defining diseases as competing causes of death. This study estimates the HIV mortality rate and their risk factors with regard to different causes in a large city from January 2001 to June 2013. Materials and Methods We followed-up 3137 newly diagnosed HIV non-AIDS cases. Causes of death were classified as HIV-related, non-HIV-related and external. We examined the effect of risk factors on survival using mortality rates, Kaplan-Meier plots and Cox models. Finally, we estimated survival for each main cause of death groups through Fine and Gray models. Mortality Results 182 deaths were found [14.0/1000 person-years of follow-up (py); 95% confidence interval (CI):12.0–16.1/1000 py], 81.3% of them had a known cause of death. Mortality rate by HIV-related causes and non-HIV-related causes was the same (4.9/1000 py; CI:3.7–6.1/1000 py), external was lower [1.7/1000 py; (1.0–2.4/1000 py)]. Survival Results Kaplan-Meier estimate showed worse survival in intravenous drug user (IDU) and heterosexuals than in men having sex with men (MSM). Factors associated with HIV-related causes of death include: IDU male (subHazard Ratio (sHR):3.2; CI:1.5–7.0) and <200 CD4 at diagnosis (sHR:2.7; CI:1.3–5.7) versus ≥500 CD4. Factors associated with non-HIV-related causes of death include: ageing (sHR:1.5; CI:1.4–1.7) and heterosexual female (sHR:2.8; CI:1.1–7.3) versus MSM. Factors associated with external causes of death were IDU male (sHR:28.7; CI:6.7–123.2) and heterosexual male (sHR:11.8; CI:2.5–56.4) versus MSM. Conclusion and Recommendation There are important differences in survival among transmission groups. Improved treatment is especially necessary in IDUs and heterosexual males.

[1]  Katherine E Henson,et al.  Risk of Suicide After Cancer Diagnosis in England , 2018, JAMA psychiatry.

[2]  A. Zwinderman,et al.  Changes in HIV RNA and CD4 Cell Count After Acute HCV Infection in Chronically HIV-Infected Individuals , 2015, Journal of acquired immune deficiency syndromes.

[3]  P. Sogni,et al.  Hepatitis B and human immunodeficiency virus co-infection. , 2014, World journal of gastroenterology.

[4]  A. Mocroft,et al.  Biomarkers of inflammation, coagulation and microbial translocation in HIV/HCV co-infected patients in the SMART study. , 2014, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[5]  Jack Drescher,et al.  Proposed declassification of disease categories related to sexual orientation in the International Statistical Classification of Diseases and Related Health Problems (ICD-11) , 2014, Bulletin of the World Health Organization.

[6]  C. Garriga,et al.  A low-cost, sustainable, second generation system for surveillance of people living with HIV in Spain: 10-year trends in behavioural and clinical indicators, 2002 to 2011. , 2014, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[7]  Madison,et al.  Revised surveillance case definition for HIV infection--United States, 2014. , 2014, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[8]  C. Larsen,et al.  Employment status in persons with and without HIV infection in Denmark: 1996–2011 , 2014, AIDS.

[9]  R. Paredes,et al.  Adjudicated Morbidity and Mortality Outcomes by Age among Individuals with HIV Infection on Suppressive Antiretroviral Therapy , 2014, PloS one.

[10]  L. Goodall,et al.  Late diagnosis among our ageing HIV population: a cohort study , 2014, Journal of the International AIDS Society.

[11]  C. Larsen,et al.  Educational attainment and risk of HIV infection, response to antiretroviral treatment, and mortality in HIV-infected patients , 2014, AIDS.

[12]  R. Hogg,et al.  Gender Differences in Clinical Outcomes among HIV-Positive Individuals on Antiretroviral Therapy in Canada: A Multisite Cohort Study , 2013, PloS one.

[13]  Fan Zhang,et al.  Determinants of Progression to AIDS and Death Following HIV Diagnosis: A Retrospective Cohort Study in Wuhan, China , 2013, PloS one.

[14]  P. Sullivan,et al.  The increase in global HIV epidemics in MSM , 2013, AIDS.

[15]  S. Moreno,et al.  All-cause mortality in the cohorts of the Spanish AIDS Research Network (RIS) compared with the general population: 1997–2010 , 2013, BMC Infectious Diseases.

[16]  V. Valcour,et al.  Management of human immunodeficiency virus infection in advanced age. , 2013, JAMA.

[17]  R. Weber,et al.  Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study , 2013, HIV medicine.

[18]  A. Phillips,et al.  Life expectancy living with HIV: recent estimates and future implications , 2013, Current opinion in infectious diseases.

[19]  Mardge H. Cohen,et al.  Cause-specific life expectancies after 35 years of age for human immunodeficiency syndrome-infected and human immunodeficiency syndrome-negative individuals followed simultaneously in long-term cohort studies, 1984-2008. , 2013, American journal of epidemiology.

[20]  D. Forton,et al.  Effect of hepatitis C virus on the central nervous system of HIV-infected individuals , 2012 .

[21]  E. Szumilin,et al.  Incidence, risk factors and causes of death in an HIV care programme with a large proportion of injecting drug users , 2012, Tropical medicine & international health : TM & IH.

[22]  L. Grothaus,et al.  Chronic illness burden and quality of life in an aging HIV population , 2012, AIDS care.

[23]  T. Niyonsenga,et al.  Socioeconomic Status and Survival of People with Human Immunodeficiency Virus Infection before and after the Introduction of Highly Active Antiretroviral Therapy: A Systematic Literature Review , 2012, Journal of AIDS & clinical research.

[24]  A. Esteve,et al.  Factors associated with late presentation of HIV infection in Catalonia, Spain , 2012, International journal of STD & AIDS.

[25]  D. Wantland,et al.  Exploring the contribution of general self-efficacy to the use of self-care symptom management strategies by people living with HIV infection. , 2012, AIDS patient care and STDs.

[26]  J. A. Caylà,et al.  Retraso Diagnóstico de la Infección por VIH , 2012 .

[27]  H. Putter,et al.  Competing risks in epidemiology: possibilities and pitfalls. , 2012, International journal of epidemiology.

[28]  O. Kirk,et al.  The effect of injecting drug use history on disease progression and death among HIV‐positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis , 2012, HIV medicine.

[29]  J. Blanco,et al.  Educational Gradient in HIV Diagnosis Delay, Mortality, Antiretroviral Treatment Initiation and Response in a Country with Universal Health Care , 2012, Antiviral therapy.

[30]  Margaret T May,et al.  Life expectancy of HIV-positive adults: a review. , 2011, Sexual health.

[31]  J. Castilla,et al.  Educational level and HIV disease progression before and after the introduction of HAART: a cohort study in 989 HIV seroconverters in Spain , 2011, Sexually Transmitted Infections.

[32]  J. Miro,et al.  Epidemiological characteristics and predictors of late presentation of HIV infection in Barcelona (Spain) during the period 2001-2009 , 2011, AIDS research and therapy.

[33]  J. Castilla,et al.  Mortality by causes in HIV-infected adults: comparison with the general population , 2011, BMC public health.

[34]  Carlos Del Rio,et al.  The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  N. Ford,et al.  Association of aging and survival in a large HIV-infected cohort on antiretroviral therapy , 2011, AIDS.

[36]  D. Wantland,et al.  Unhealthy substance-use behaviors as symptom-related self-care in persons with HIV/AIDS. , 2011, Nursing & health sciences.

[37]  J. Caylà,et al.  [Is it possible to reduce the delay in diagnosing HIV infection?]. , 2010, Enfermedades Infecciosas y Microbiologia Clinica.

[38]  J. A. Caylà,et al.  [Is it possible to reduce the delay in diagnosing HIV infection?]. , 2010, Enfermedades infecciosas y microbiologia clinica.

[39]  J. Castilla,et al.  Retraso diagnóstico de la infección por el virus de la inmunodeficiencia humana en España , 2010 .

[40]  Ross J. Harris,et al.  Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  J. Carton,et al.  Association of HIV transmission categories with sociodemographic, viroimmunological and clinical parameters of HIV-infected patients , 2009, Epidemiology and Infection.

[42]  J. García,et al.  [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)]. , 2009, Enfermedades infecciosas y microbiologia clinica.

[43]  T. Durant,et al.  Late HIV Diagnosis and Determinants of Progression to AIDS or Death after HIV Diagnosis among Injection Drug Users, 33 US States, 1996–2004 , 2009, PloS one.

[44]  Ross J. Harris,et al.  Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies , 2008, The Lancet.

[45]  L. Berkman,et al.  Unemployment as a risk factor for AIDS and death for HIV-infected patients in the era of highly active antiretroviral therapy , 2008, Sexually Transmitted Infections.

[46]  J. Caylà,et al.  Individual and community-level effects in the socioeconomic inequalities of AIDS-related mortality in an urban area of southern Europe , 2007, Journal of Epidemiology and Community Health.

[47]  F. Lert,et al.  Socioeconomic differences in the impact of HIV infection on workforce participation in France in the era of highly active antiretroviral therapy. , 2007, American journal of public health.

[48]  J. Caylà,et al.  AIDS mortality before and after the introduction of highly active antiretroviral therapy: does it vary with socioeconomic group in a country with a National Health System? , 2006, European journal of public health.

[49]  F. Lert,et al.  Predictors identified for losses to follow-up among HIV-seropositive patients. , 2006, Journal of clinical epidemiology.

[50]  G. Binefa,et al.  [Survival changes among AIDS cases in Catalonia, Spain (1981-2001)]. , 2006, Medicina clínica (Ed. impresa).

[51]  R. Gispert,et al.  Cambio de la supervivencia de los casos de sida en Cataluña (1981-2001) , 2006 .

[52]  Giuseppe Costa,et al.  Educational inequalities in cause-specific mortality in middle-aged and older men and women in eight western European populations , 2005, The Lancet.

[53]  Kholoud Porter,et al.  Determinants of survival following HIV-1 seroconversion after the introduction of HAART , 2003, The Lancet.

[54]  D. Osmond,et al.  Trends in causes of death among persons with acquired immunodeficiency syndrome in the era of highly active antiretroviral therapy, San Francisco, 1994-1998. , 2002, The Journal of infectious diseases.

[55]  Jonathan AC Sterne,et al.  Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.

[56]  J. González,et al.  Recomendaciones de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en pacientes adultos infectados por el virus de la inmunodeficiencia humana en el año 2002 , 2002 .

[57]  J. Caylà,et al.  Impact of Adherence and Highly Active Antiretroviral Therapy on Survival in HIV‐Infected Patients , 2002, Journal of acquired immune deficiency syndromes.

[58]  K. Tashima,et al.  Human immunodeficiency virus infection, AIDS, and smoking cessation: the time is now. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[59]  D. Ng-Mak,et al.  The Latino mortality paradox: a test of the "salmon bias" and healthy migrant hypotheses. , 1999, American journal of public health.

[60]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[61]  A. Zuger Adherence to highly active antiretroviral therapy. , 1997, AIDS clinical care.

[62]  R. Scribner Mortality among Hispanics. , 1994, JAMA.

[63]  M. Sprangers,et al.  Predictors and correlates of adherence to combination antiretroviral therapy (ART) for chronic HIV infection: a meta-analysis. , 2014, BMC medicine.

[64]  Gabinet Tècnic de Programació Distribució territorial de la renda familiar disponible per càpita a Barcelona. 2013 , 2014 .

[65]  [Consensus Statement by GeSIDA/National AIDS Plan Secretariat on antiretroviral treatment in adults infected by the human immunodeficiency virus (Updated January 2013)]. , 2013, Enfermedades Infecciosas y Microbiologia Clinica.

[66]  J. Caylà,et al.  [Delay in diagnosis of HIV infection]. , 2012, Revista espanola de sanidad penitenciaria.

[67]  J. Castilla,et al.  [Delayed diagnosis of HIV infection in Spain]. , 2010, Enfermedades Infecciosas y Microbiologia Clinica.

[68]  A. Orcau,et al.  Increase in the non-HIV-related deaths among AIDS cases in the HAART era. , 2008, Current HIV research.

[69]  J. Miro,et al.  [Recommendations of the Spanish AIDS Study Group (GESIDA) and the National Aids Plan (PNS) for antiretroviral treatment in adult patients with human immunodeficiency virus infection in 2002]. , 2002, Enfermedades infecciosas y microbiologia clinica.

[70]  European Monitoring Center for Drugs and Drug Addiction Annual Report on the State of the Drugs Problem in the European Union, Portugal, 1997 , 1998 .